Comparative Pharmacology
Head-to-head clinical analysis: ALTAVERA versus LOESTRIN FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTAVERA versus LOESTRIN FE 1 5 30.
ALTAVERA vs LOESTRIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
None Documented
None Documented
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive